If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How do I get Zepbound® (tirzepatide) vials?
Zepbound 2.5 and 5 mg vials are available exclusively through LillyDirect's self-pay pharmacy channel for patients with a prescription from their healthcare provider.
See important safety information, including boxed warning, in the attached prescribing information.
Zepbound Vial Availability
Eli Lilly and Company has created a new self-pay pharmacy component of LillyDirect® where patients with a valid, on-label, electronic prescription from the health care provider of their choice can purchase Zepbound 2.5 and 5 mg vials.1
Zepbound 2.5 and 5 mg vials are available.
As of August 27, 2024, the Zepbound 2.5 and 5 mg vials are available via LillyDirect's self-pay pharmacy channel.1,2
Offering Zepbound single-dose vials in higher dosage strengths could increase the potential for dose-splitting, which is not contemplated by the FDA-approved label and may pose patient-safety risks. Lilly will continue to assess market conditions and patient-safety issues in determining optimal presentations and strengths to ensure appropriate patients can affordably access this Lilly medicine.2
In a clinical trial, patients without type 2 diabetes who were treated with a 5 mg weekly dose of tirzepatide, along with a reduced calorie diet and increased physical activity, achieved an average decrease in weight of 15% compared to 3.1% for placebo over 72 weeks.3
Zepbound Vials List Price at LillyDirect
Distributing the vials via LillyDirect’s self-pay pharmacy channel offers transparent pricing for the Zepbound single-dose vials, cutting out extra costs to pass savings directly to patients. This new option helps adults with obesity access the medicine they need, including those
- not eligible for the Zepbound savings card program
- without employer coverage, and
- who need to self-pay outside of insurance.1
Distributing the vials via LillyDirect ensures patients and providers can trust they are receiving genuine Lilly medicine.1
For information about the cost or price of Zepbound, please visit https://www.lillypricinginfo.com/zepbound for English or https://www.lillypricinginfo.com/es/zepbound for Spanish.
To learn more about LillyDirect, please visit: https://lillydirect.lilly.com.1
Enclosed Prescribing Information
References
1Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity. Press release. Eli Lilly and Company; August 27, 2024. Accessed October 3, 2024. https://investor.lilly.com/news-releases/news-release-details/lilly-releases-zepboundr-tirzepatide-single-dose-vials-expanding
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: October 03, 2024